US equities
|
MU
$1,029.00
▼-0.66%
NVDA
$229.28
▼-0.52%
SPCX
$162.57
▲+1.25%
TSLA
$382.70
▲+2.05%
AAPL
$336.64
▼-1.11%
MSFT
$535.07
▲+2.38%
AMZN
$262.43
▲+3.29%
META
$718.67
▼-0.31%
MU
$1,029.00
▼-0.66%
NVDA
$229.28
▼-0.52%
SPCX
$162.57
▲+1.25%
TSLA
$382.70
▲+2.05%
AAPL
$336.64
▼-1.11%
MSFT
$535.07
▲+2.38%
AMZN
$262.43
▲+3.29%
META
$718.67
▼-0.31%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Relay Therapeutics, Inc. - Common Stock
(NQ:
RLAY
)
17.88
+0.47 (+2.70%)
Delayed Quote
Updated: 4:00 PM EDT, Oct 9, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Relay Therapeutics, Inc. - Common Stock
< Previous
1
2
3
Next >
Relay Therapeutics to Participate in Two Upcoming Investor Conferences in September
September 01, 2026
From
Relay Therapeutics, Inc.
Via
GlobeNewswire
Relay Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Updates
August 06, 2026
From
Relay Therapeutics, Inc.
Via
GlobeNewswire
Relay Therapeutics to Announce Second Quarter 2026 Financial Results and Corporate Highlights on August 6, 2026
July 30, 2026
From
Relay Therapeutics, Inc.
Via
GlobeNewswire
Relay Therapeutics to Participate in Two Upcoming Investor Conferences in June
May 27, 2026
From
Relay Therapeutics, Inc.
Via
GlobeNewswire
Relay Therapeutics Announces Pricing of Public Offering of Common Stock
May 20, 2026
From
Relay Therapeutics, Inc.
Via
GlobeNewswire
Relay Therapeutics Announces Proposed Public Offering of Common Stock
May 19, 2026
From
Relay Therapeutics, Inc.
Via
GlobeNewswire
Relay Therapeutics Announces Initial Clinical Data Demonstrating That Zovegalisib Has Potential for Differentiated Safety and Efficacy in Patients with PIK3CA-Driven Vascular Anomalies
May 19, 2026
From
Relay Therapeutics, Inc.
Via
GlobeNewswire
Relay Therapeutics Reports First Quarter 2026 Financial Results and Corporate Updates
May 05, 2026
From
Relay Therapeutics, Inc.
Via
GlobeNewswire
Relay Therapeutics to Announce First Quarter 2026 Financial Results and Corporate Highlights on May 5, 2026
April 29, 2026
From
Relay Therapeutics, Inc.
Via
GlobeNewswire
Relay Therapeutics Announces Clinical Data for Zovegalisib plus Atirmociclib Triplet Combination Supportive of Further Development in Frontline Metastatic Breast Cancer
April 27, 2026
From
Relay Therapeutics, Inc.
Via
GlobeNewswire
Relay Therapeutics to Present Initial Clinical Data on Zovegalisib in Vascular Anomalies at the International Society for the Study of Vascular Anomalies World Congress 2026
April 02, 2026
From
Relay Therapeutics, Inc.
Via
GlobeNewswire
Relay Therapeutics Announces Data from Zovegalisib + Fulvestrant at the Phase 3 Dose of 400mg BID Fed at ESMO Targeted Anticancer Therapies Congress 2026
March 16, 2026
From
Relay Therapeutics, Inc.
Via
GlobeNewswire
Relay Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Outlines Anticipated 2026 Milestones
February 26, 2026
From
Relay Therapeutics, Inc.
Via
GlobeNewswire
Relay Therapeutics to Participate in Two Upcoming Investor Conferences in March
February 23, 2026
From
Relay Therapeutics, Inc.
Via
GlobeNewswire
Relay Therapeutics to Announce Fourth Quarter and Full Year 2025 Financial Results and Corporate Highlights on February 26, 2026
February 19, 2026
From
Relay Therapeutics, Inc.
Via
GlobeNewswire
Relay Therapeutics to Participate in Guggenheim Emerging Outlook: Biotech Summit 2026
February 04, 2026
From
Relay Therapeutics, Inc.
Via
GlobeNewswire
Relay Therapeutics Announces Zovegalisib Granted Breakthrough Therapy Designation by U.S. FDA for PIK3CA-mutant, HR+/HER2- Advanced Breast Cancer
February 03, 2026
From
Relay Therapeutics, Inc.
Via
GlobeNewswire
Cancer Drug Developers Secure Regulatory Clarity as FDA Reshapes Approval Standards
December 16, 2025
Issued on behalf of Oncolytics Biotech Inc.
From
Equity Insider
Via
GlobeNewswire
Relay Therapeutics Announces Efficacy Subset Analysis of Zovegalisib (RLY-2608) + Fulvestrant in Breast Cancer Patients Pre-Treated with SERD or with ESR1 Mutations at SABCS 2025
December 12, 2025
From
Relay Therapeutics, Inc.
Via
GlobeNewswire
Relay Therapeutics Reports Third Quarter 2025 Financial Results and Corporate Updates
November 06, 2025
From
Relay Therapeutics, Inc.
Via
GlobeNewswire
Relay Therapeutics to Participate in Two Upcoming Investor Conferences in November
November 03, 2025
From
Relay Therapeutics, Inc.
Via
GlobeNewswire
Relay Therapeutics to Announce Third Quarter 2025 Financial Results and Corporate Highlights on November 6, 2025
October 30, 2025
From
Relay Therapeutics, Inc.
Via
GlobeNewswire
Relay Therapeutics to Participate in Two Upcoming Investor Conferences in September
August 28, 2025
From
Relay Therapeutics, Inc.
Via
GlobeNewswire
Relay Therapeutics Reports Second Quarter 2025 Financial Results and Corporate Updates
August 07, 2025
From
Relay Therapeutics, Inc.
Via
GlobeNewswire
Relay Therapeutics to Announce Second Quarter 2025 Financial Results and Corporate Highlights on August 7, 2025
July 31, 2025
From
Relay Therapeutics, Inc.
Via
GlobeNewswire
Relay Therapeutics Appoints Claire Mazumdar, Ph.D., to Board of Directors
June 11, 2025
From
Relay Therapeutics, Inc.
Via
GlobeNewswire
Relay Therapeutics Announces Updated Data for RLY-2608 + Fulvestrant Further Demonstrating Clinically Meaningful Progression Free Survival at ASCO 2025
June 02, 2025
From
Relay Therapeutics, Inc.
Via
GlobeNewswire
Relay Therapeutics to Participate in Two Upcoming Investor Conferences in June
May 29, 2025
From
Relay Therapeutics, Inc.
Via
GlobeNewswire
Relay Therapeutics Reports First Quarter 2025 Financial Results and Corporate Updates
May 05, 2025
From
Relay Therapeutics, Inc.
Via
GlobeNewswire
Relay Therapeutics to Announce First Quarter 2025 Financial Results and Corporate Highlights on May 5, 2025
April 28, 2025
From
Relay Therapeutics, Inc.
Via
GlobeNewswire
< Previous
1
2
3
Next >
